Autonomous targeting of infectious superspreaders using engineered transmissible therapies.
Infectious disease treatments, both pharmaceutical and vaccine, face three universal challenges: the difficulty of targeting treatments to high-risk 'superspreader' populations who drive the great majority of disease spread, behavioral barriers in the host population (such as poor complian...
Main Authors: | Vincent T Metzger, James O Lloyd-Smith, Leor S Weinberger |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-03-01
|
Series: | PLoS Computational Biology |
Online Access: | http://europepmc.org/articles/PMC3060167?pdf=render |
Similar Items
-
Superspreading in early transmissions of COVID-19 in Indonesia
by: Agus Hasan, et al.
Published: (2020-12-01) -
Effects of environmental variability on superspreading transmission events in stochastic epidemic models
by: Nika Shakiba, et al.
Published: (2021-01-01) -
Evidence that coronavirus superspreading is fat-tailed
by: Wong, Felix, et al.
Published: (2020) -
Are SARS Superspreaders Cloud Adults?
by: Stefano Bassetti, et al.
Published: (2005-04-01) -
Effects of superspreaders in spread of epidemic
by: Fujie, Ryo, et al.
Published: (2016)